Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Por:
Zozaya, N, Abdalla, F, Zamora, SA, Filgueiras, JB, Carrillo, JMC, Sanchez, OD, Sinisterra, FD, Garcia-Ruiz, A, Pinto, PH, Manfredi, A, Olmos, JM, Luna, PMD, Puig, L, Ros, S, HIdalgo-Vega, A
Publicada:
18 ago 2022
Ahead of Print:
1 abr 2022
Resumen:
Background Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. Research design and methods The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Results Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Conclusions Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.
Filiaciones:
Zozaya, N:
Weber, Dept Hlth Econ, Madrid, Spain
Univ Las Palmas Gran Canaria, Dept Quantitat Methods Econ & Management, Las Palmas Gran Canaria, Spain
Abdalla, F:
Weber, Dept Hlth Econ, Madrid, Spain
Zamora, SA:
Dept Management Psoriasis & Psoriat Arthrit Patie, Barcelona, Spain
Filgueiras, JB:
Dept Pharm, Ferrol Univ Hosp Complex, La Coruna, Spain
Carrillo, JMC:
Germans Trias I Pujol Univ Hosp, Dept Dermatol, Badalona, Spain
Sanchez, OD:
Son Espases Univ Hosp, Spanish Soc Hosp Pharm SEFH, Dept Management, Dept Pharm, Illes Balears, Spain
Sinisterra, FD:
Doctor Peset Univ Hosp, Dept Management, Valencia, Spain
Garcia-Ruiz, A:
Univ Malaga, Biomed Res Inst Malaga IBIMA, Hlth Econ & Rat Use Med, Dept Pharmacol & Clin Therapeut, Malaga, Spain
Pinto, PH:
La Paz Univ Hosp, Dept Dermatol, Madrid, Spain
Manfredi, A:
Dept Management Psoriasis & Psoriat Arthrit Patie, Barcelona, Spain
Olmos, JM:
Andalusian Publ Hlth Sch EASP, Granada, Spain
Luna, PMD:
Gregorio Maranon Univ Hosp, Dept Nursing, Madrid, Spain
Puig, L:
Univ Autonoma Barcelona, Dept Dermatol, Hosp Santa Creu & St Pau, Barcelona, Spain
Ros, S:
Hosp Santa Creu & Sant Pau, Dept Dermatol Rheumatol & Cardiac Transplantat, Barcelona, Spain
HIdalgo-Vega, A:
Weber Fdn, Madrid, Spain
Univ Castilla La Mancha, Dept Econ Anal & Finances, Toledo, Spain
hybrid
|